SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Caplin Point Laboratories moves up as its arm gets USFDA’s nod for Ropivacaine Hydrochloride injection

13 Apr 2020 Evaluate
Caplin Point Laboratories is currently trading at Rs. 309.00, up by 18.95 points or 6.53% from its previous closing of Rs. 290.05 on the BSE.

The scrip opened at Rs. 307.00 and has touched a high and low of Rs. 310.00 and Rs. 285.00 respectively. So far 8060 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 466.00 on 06-Jun-2019 and a 52 week low of Rs. 180.00 on 24-Mar-2020.

Last one week high and low of the scrip stood at Rs. 310.00 and Rs. 274.05  respectively. The current market cap of the company is Rs. 2313.16 crore.

The promoters holding in the company stood at 69.03%, while Institutions and Non-Institutions held 7.47% and 23.50% respectively.

Caplin Point Laboratories’ wholly owned subsidiary -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ropivacaine Hydrochloride injection USP, 0.2 % in 40 mg/20 mL (2 mg/mL), 0.5 % in 100 mg/20 mL (5 mg/mL), 0.5 % in 150 mg/30 mL (5 mg/mL) and 1 % in 200 mg/20 mL (10 mg/mL) Single-dose vial presentations, a generic therapeutic equivalent version of (RLD), NAROPIN Injection, of Fresenius Kabi USA LLC.

According to IQVIATM (IMS Health), Ropivacaine Hydrochloride injection USP had US sales data of approximately $34 million for the 12-month period ending Dec 2019. The company, has developed and filed 16 ANDAs on its own and with partners, with 8 approvals so far. Ropivacaine Hydrochloride is a long acting local anesthetic drug used for surgery or acute pain management.

Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.

Caplin Point Lab Share Price

1772.50 6.05 (0.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×